PERRIGO COMPANY PLC

(PRGO)
  Report
Delayed Nyse  -  04:00 2022-08-08 pm EDT
42.58 USD   -0.93%
08/02Perrigo announces quarterly dividend
PR
08/02Perrigo Company plc Declares Quarterly Dividend, Payable on September 20, 2022
CI
07/27Perrigo to release second quarter 2022 financial results on august 9, 2022
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Perrigo Company plc Announces U.S. FDA Approval for Omeprazole Magnesium Delayed-Release Mini Capsules

05/26/2022 | 09:17am EDT

Perrigo Company plc announced that it has received final approval from the U.S. Food and Drug Administration for Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC). Perrigo expects to launch Omeprazole Minis later this year. This launch represents a first-to-market mini capsule form of omeprazole, which is indicated for treatment of frequent heartburn. This capsule is 70% smaller than the tablet version of omeprazole that is currently available, providing a differentiated and preferred product offering for consumers. The product will be marketed under retailer's store brand labels comparable to Prilosec OTC.


© S&P Capital IQ 2022
All news about PERRIGO COMPANY PLC
08/02Perrigo announces quarterly dividend
PR
08/02Perrigo Company plc Declares Quarterly Dividend, Payable on September 20, 2022
CI
07/27Perrigo to release second quarter 2022 financial results on august 9, 2022
PR
07/21Will A Nonprescription Birth Control Pill Be FDA's First Approval Under Its Long-Awaite..
AQ
07/15PERRIGO : Independent Auditors' Report - Form 8-K/A
PU
07/15PERRIGO CO PLC Completion of Acquisition or Disposition of Assets, Financial Statement..
AQ
07/14PERRIGO CO PLC : Change in Directors or Principal Officers (form 8-K)
AQ
07/14Perrigo Company plc Appoints Albert A. Manzone to Serve as A Member of the Board of Dir..
CI
07/11SECTOR UPDATE : Health Care Stocks Lean Lower Pre-Bell Monday
MT
07/11Perrigo Unit Files Application With FDA for Switch to Over-The-Counter for Birth Contro..
MT
More news
Analyst Recommendations on PERRIGO COMPANY PLC
More recommendations
Financials (USD)
Sales 2022 4 501 M - -
Net income 2022 - - -
Net Debt 2022 3 688 M - -
P/E ratio 2022 -77,4x
Yield 2022 2,54%
Capitalization 5 729 M 5 729 M -
EV / Sales 2022 2,09x
EV / Sales 2023 1,90x
Nbr of Employees 9 900
Free-Float 99,4%
Chart PERRIGO COMPANY PLC
Duration : Period :
Perrigo Company plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERRIGO COMPANY PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 42,58 $
Average target price 50,00 $
Spread / Average Target 17,4%
EPS Revisions
Managers and Directors
Murray S. Kessler President, Chief Executive Officer & Director
Eduardo Guarita Bezerra Chief Financial Officer & Executive Vice President
Orlando D. Ashford Chairman
Thomas M. Farrington Chief Information Officer & Executive VP
Grainne Quinn Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
PERRIGO COMPANY PLC10.49%5 783
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
PFIZER, INC.-16.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.1.95%244 068